Table 1.
Sociodemographic and clinical characteristics of participants
| Olz (n=35) |
Quet (n=29) |
HC (n=32) |
Statistics | |
|---|---|---|---|---|
| Age (years) | 38 (22–55) | 42 (20–58) | 35 (28–45) | df =2, P=0.078 |
| Sex | ||||
| Female | 20 (57.1%) | 15 (51.7%) | 11(34.4%) | χ2 =3.71, P=0.156 |
| Male | 15 (42.9%) | 14 (48.3%) | 21 (65.6%) | |
| Smoking | ||||
| Yes | 18 (51.4%) | 12 (41.4%) | 17 (53.1%) | χ2 =0.91, P=0.61 |
| No | 17 (48.6%) | 17 (58.6%) | 15 (46.9%) | |
| TC (mg/dL) | 194 (142–293) | 172.5 (102–235) | 188.5 (103–220) |
df =2, P=0.042 Olz and Quet: P=0.04 Olz and HC: P=0.02 Quet and HC: P=0.71 |
| TG (mg/dL) | 166.7 (48–389) | 161.1 (42–298) | 159.3 (89–242) | df =2, P=0.88 |
| LDL-C (mg/dL) | 129.4 ± 34.44 | 108 ± 29.19 | 110.78 ± 30.59 |
F =8.92, P=0.038 Olz and Quet: P=0.03 Olz and HC: P=0.04 Quet and HC: P=0.81 |
| HDL-C (mg/dL) | 36 (24–57) | 39.5 (30–51) | 40 (27–56) | df =2, P=0.472 |
| BMI (kg/m2) | 23.44 ± 1.67 | 23.41 ± 0.68 | 23.21 ± 0.77 | F =0.92, P=0.4 |
| Daily dose (mg)* | 265.71 ± 87.26 | 683.91 ± 155.48 | – | t =−13.56, P<0.01 |
Notes:
*
Represents chlorpromazine-equivalent dose. Significant differences between groups are highlighted in bold. Age, TC, and HDL-C are represented as median (range); TG, LDL-C, BMI, and Daily dose are represented as mean ± standard deviation.
Abbreviations: BMI, body mass index; HC, healthy control; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Olz, olanzapine group; Quet, quetiapine group; TC, total cholesterol; TG, triglyceride.